Case study: evidentiary standards for extrapolation
Drug indicated for treatment of partial seizures in adults, pediatric patients down to age 6
Extension of labeling to age 1 month based on establishing:
- similarity of disease
- similarity of response to treatment
- dosing regimen that resulted in plasma levels in therapeutic range
- acceptable safety profile